异种心包主动脉瓣新瓣叶成形术与生物瓣置换的对比研究
本研究比较了异种心包主动脉瓣新瓣叶成形术(xAVNeo)与生物瓣置换术(SAVR)在严重主动脉瓣狭窄伴小主动脉根患者中的6年临床结局。倾向性匹配后共222例患者,两组早期死亡率和6年生存率相当,但xAVNeo组的结构性瓣膜退化和再手术率更高。
要点
- xAVNeo与SAVR的早期死亡率和6年生存率无显著差异。
- xAVNeo组6年免再手术率84.8%,低于SAVR组的100%。
- xAVNeo组瓣叶硬化再手术线性化率1.92%/患者年,SAVR组0.26%/患者年。
核心结论
- xAVNeo与SAVR的早期临床结局和6年生存率相当,但xAVNeo使用牛心包与更高的结构性瓣膜退化和更低的免再手术率相关。
研究设计与样本
- 回顾性队列研究,纳入2003至2018年412例严重主动脉瓣狭窄伴小主动脉根患者,其中xAVNeo组114例、生物瓣组298例,倾向性匹配后共222例。
- 平均随访3.4±3.1年,随访完整率95%。
主要发现
- 早期死亡率SAVR组8.1% vs xAVNeo组9.9%(OR 1.25,95%CI 0.51-2.89)。
- 6年估计生存率SAVR组89.9% vs xAVNeo组88.8%(OR 1.07,95%CI 0.49-2.34)。
- xAVNeo组新瓣叶进行性退化导致平均跨瓣压差从6.1±2.3 mm Hg增至22.7±11.5 mm Hg(P < .0001)。
- xAVNeo组因瓣叶硬化再手术的线性化率为1.92%/患者年,SAVR组为0.26%/患者年(率比7.41,95%CI 0.95-333.7)。
- 6年免再手术率xAVNeo组为84.8%,低于SAVR组的100%。
临床怎么用
- 对于严重主动脉瓣狭窄伴小主动脉根患者,xAVNeo可作为一种选择,但需充分告知患者其结构性瓣膜退化和再手术风险高于生物瓣置换。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical aortic valve replacement (SAVR) for patients with aortic valve stenosis (AS) with small aortic root is associated with a higher rate of prosthesis-patient mismatch and suboptimal clinical outcomes. Aortic valve neocuspidization using xenologous pericardium (xAVNeo) has shown a favorable hemodynamic performance. The aim was to compare 6-year clinical outcomes of xAVNeo with SAVR. METHODS: Between 2003 and 2018, 412 patients with severe AS and small aortic root received either xAVNeo (n = 114) or bioprosthesis (n = 298). After propensity matching the cohort included 222 patients. The primary endpoints were early mortality, 6-year mortality, and freedom from reoperation. Mean follow-up averaged 3.4 ± 3.1 years and was 95% complete. RESULTS: Early mortality was 8.1% for the SAVR group versus 9.9% for the xAVNeo group (odds ratio, 1.25; 95% confidence interval, 0.51-2.89). The estimated survival probabilities at 6 years for the SAVR and xAVNeo cohorts were 89.9% and 88.8%, respectively (odds ratio, 1.07; 95% confidence interval, 0.49-2.34). Progressive degeneration of the neocusps resulted in a mean gradient increase from 6.1 ± 2.3 mm Hg to 22.7 ± 11.5 mm Hg (P < .0001); cusp sclerosis was the most common indication for reoperation in the xAVNeo group with a linearized rate of 1.92% versus 0.26% per patient-year (rate ratio, 7.41; 95% confidence interval, 0.95-333.7). The freedom from reoperation was 84.8% at 6 years, inferior to that of the SAVR group (100%). CONCLUSIONS: Early clinical outcomes and 6-year survival rates after xAVNeo and SAVR were comparable. However xAVNeo using bovine pericardium was associated with a higher rate of structural valve deterioration and inferior freedom from reoperation when compared with SAVR.
引用
- Mitrev Z, Risteski P, Todorovska M, et al. Aortic Valve Neocuspidization Using Xenologous Pericardium Versus Bioprosthetic Valve Replacement. Ann Thorac Surg. 2021. PMID: 34048758. doi:10.1016/j.athoracsur.2021.04.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。